How tuning body signals with closed-loop sound and chill tech may ease dissociation and anhedonia, offering drug-free add-ons to therapy.
|Slideshows|February 12, 2018
Lifestyle, Personality, and Metabolic Changes in the Elderly
Author(s)Mark L. Fuerst
Three new studies on genetic risk factors and lifestyle; the transition from cognitive health to Alzheimer disease; and metabolic syndrome in depressed older adults.
Advertisement
Advertisement
Related to this article
New real-world studies show Vraylar boosts depression relief, functioning, and quality of life in MDD and bipolar I patients beyond clinical trials.
Phase 2 MOONLIGHT-1 shows JNJ-5120/PIPE-307 misses day‑5 MADRS improvement in MDD, yet remains well tolerated as J&J reviews next steps.
Experts dissect 10 common antidepressant myths, separating evidence from fear on efficacy, addiction, suicide risk, withdrawal, and safe tapering.
Health Canada has authorized a 200-participant phase 2 trial testing a single psilocybin dose for major depressive disorder, with dosing set to begin in 2027.
Phase 1 driving simulation finds bedtime GlyphAllo for major depressive disorder shows no next-morning driving impairment, while advancing allopregnanolone-based oral treatment development.
Learn why SSRIs impair sex and how bupropion, PDE5 inhibitors, buspirone, and newer agents can prevent or reverse antidepressant sexual side effects.
Experts unpack screening for sexual dysfunction in psychiatric care, menopause and meds impacts, and when flibanserin may help restore desire.
Advertisement
Advertisement
Trending on Psychiatric Times
1
FDA Hearing on Psychedelic Medicine Reveals a Field Divided on the Road to Approval
2
Centanafadine For Comorbid ADHD and Anxiety: Talking New Data With John Kraus, MD, PhD
3
The Silence Between the Questions: Reflections on Adolescent Suicide Risk When Intent Is Unclear
4
New Adult ADHD Guidelines: What Resources Are Coming Soon
5